| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Brigitte Konta, Wilhelm Fran. The treatment of Parkinson's disease with dopamine agonists. GMS health technology assessment. vol 4. 2011-07-14. PMID:21289911. |
basically there is a good effectiveness of dopamine agonists the reduce dyskinesia and this differences are statistically significant. |
2011-07-14 |
2023-08-12 |
Not clear |
| Luping Z Huang, Carla Campos, Jason Ly, F Ivy Carroll, Maryka Qui. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology. vol 60. issue 6. 2011-07-12. PMID:21232546. |
we first tested the drugs in l-dopa-treated rats with a near-complete striatal dopamine lesion (>99%), the standard rodent dyskinesia model. |
2011-07-12 |
2023-08-12 |
rat |
| I-Ching Lai, Geng-Han Mo, Mao-Liang Chen, Ying-Chieh Wang, Jen-Yeu Chen, Ding-Lieh Liao, Ya-Mei Bai, Chao-Cheng Lin, Tzu-Ting Chen, Ying-Jay Lio. Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia. European journal of clinical pharmacology. vol 67. issue 4. 2011-07-11. PMID:21181138. |
the pathogenesis of dyskinesia may result from divergent changes in dopamine d1 receptors (drd1) and dopamine d2 receptors (drd2) in the brain while aging. |
2011-07-11 |
2023-08-12 |
Not clear |
| Zvezdan Pirtoše. Myths and realities of continuous dopaminergic stimulation. Psychiatria Danubina. vol 23. issue 1. 2011-06-02. PMID:21448103. |
continuous dopaminergic stimulation has been shown to dramatically improve motor fluctuations and dyskinesia by modifications of oral treatment (dopamine agonists, smaller, more frequent levodopa doses, controlled-release formulation of levodopa, addition of agents that slow down the catabolism of dopamine, such as inhibitors of catechol-o-methyl transferase and monoamine oxidase), transdermal delivery (rotigotine), infusion therapies (intravenous levodopa, subcutaneous application of apomorphine and lisuride, duodenal infusion of levodopa) and deep brain stimulation of the subthalamic nucleus. |
2011-06-02 |
2023-08-12 |
Not clear |
| Stefania Fasano, Erwan Bezard, Angela D'Antoni, Veronica Francardo, Marzia Indrigo, Li Qin, Sandra Doveró, Milica Cerovic, M Angela Cenci, Riccardo Brambill. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proceedings of the National Academy of Sciences of the United States of America. vol 107. issue 50. 2011-05-12. PMID:21115823. |
l-dopa-induced dyskinesia (lid) is a common debilitating complication of dopamine replacement therapy in parkinson's disease. |
2011-05-12 |
2023-08-12 |
mouse |
| O Rasco. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. European journal of neurology. vol 18 Suppl 1. 2011-04-29. PMID:21255197. |
continuous dopamine stimulation (cds) is a concept that refers to the hypothesis that more continuous dopamine-receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. |
2011-04-29 |
2023-08-12 |
Not clear |
| Sergi Ferré, Carmen Lluis, José Luis Lanciego, Rafael Franc. Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamine D₁-D₃ receptor heteromer. CNS & neurological disorders drug targets. vol 9. issue 5. 2011-03-01. PMID:20632968. |
finally, it will be important to identify receptor heteromers that are involved in the pathogenesis of diseases, such as the recently discovered dopamine d₁-d₃ receptor heteromer, which might play a key role in l-dopa-induced dyskinesia in parkinson's disease. |
2011-03-01 |
2023-08-12 |
Not clear |
| Marios Politi. Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? BMC medicine. vol 8. 2011-03-01. PMID:21126348. |
it has been suggested that graft-induced dyskinesias could be related to fiber outgrowth from the graft causing increased dopamine release, that could be related to the failure of grafts to restore a precise distribution of dopaminergic synaptic contacts on host neurons or may also be induced by inflammatory and immune responses around the graft. |
2011-03-01 |
2023-08-12 |
human |
| Louisa Clare Johnston, Michael John Jackson, Sarah Rose, Andrew Christopher McCreary, Peter Jenne. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Movement disorders : official journal of the Movement Disorder Society. vol 25. issue 13. 2011-01-26. PMID:20721904. |
long-acting full dopamine d(2) agonists produce less dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-treated primates and in parkinson's disease than effective antiparkinsonian doses of levodopa. |
2011-01-26 |
2023-08-12 |
Not clear |
| Louisa Clare Johnston, Michael John Jackson, Sarah Rose, Andrew Christopher McCreary, Peter Jenne. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Movement disorders : official journal of the Movement Disorder Society. vol 25. issue 13. 2011-01-26. PMID:20721904. |
these results suggest that the partial d(2) agonist pardoprunox (slv308) is less likely to prime for dyskinesia or to lead to the expression of dyskinesia than either levodopa or full dopamine agonists. |
2011-01-26 |
2023-08-12 |
Not clear |
| Renju Kuriakose, A Jon Stoess. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Progress in brain research. vol 184. 2011-01-21. PMID:20887875. |
evaluation of central pharmacokinetics of levodopa action by pet has demonstrated the role of increased synaptic dopamine turnover and downregulation of the dopamine transporter in the pathophysiology of levodopa-induced dyskinesias. |
2011-01-21 |
2023-08-12 |
Not clear |
| M Angela Cenci, Christine Konrad. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Progress in brain research. vol 183. 2010-12-27. PMID:20696322. |
dopamine (da) replacement therapy with l-dopa remains the most effective treatment for parkinson's disease, but causes dyskinesia (abnormal involuntary movements) in the vast majority of the patients. |
2010-12-27 |
2023-08-12 |
Not clear |
| Robert T Egel, George E Hoganson, M Ammar Katerji, Martin J Borenstei. Zonisamide ameliorates symptoms of secondary paroxysmal dystonia. Pediatric neurology. vol 43. issue 3. 2010-12-06. PMID:20691944. |
a number of medications have been used with varying success to treat the symptoms of generalized, focal, and paroxysmal dyskinesias; these agents include anticonvulsant, benzodiazepine, neuroleptic, dopaminergic, dopamine antagonist, and carbonic anhydrase inhibitor types. |
2010-12-06 |
2023-08-12 |
Not clear |
| Giacomo Koc. rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets. Restorative neurology and neuroscience. vol 28. issue 4. 2010-12-02. PMID:20714078. |
long-term therapy with levodopa and dopamine agonists in parkinson's disease (pd) patients is complicated by the development of fluctuations in motor response, such as levo-dopa induced dyskinesia (lid). |
2010-12-02 |
2023-08-12 |
Not clear |
| Ji-Kyung Choi, Joseph B Mandeville, Y Iris Chen, Peter Grundt, Susanta K Sarkar, Amy H Newman, Bruce G Jenkin. Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists. Psychopharmacology. vol 212. issue 1. 2010-11-29. PMID:20628733. |
dopamine d3 receptors (d3r) may be important therapeutic targets for both drug abuse and dyskinesias in parkinson's disease; however, little is known about their functional circuitry. |
2010-11-29 |
2023-08-12 |
Not clear |
| Daniella Rylander, Martin Parent, Sean S O'Sullivan, Sandra Dovero, Andrew J Lees, Erwan Bezard, Laurent Descarries, M Angela Cenc. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Annals of neurology. vol 68. issue 5. 2010-11-29. PMID:20882603. |
striatal serotonin projections have been implicated in levodopa-induced dyskinesia by providing an unregulated source of dopamine release. |
2010-11-29 |
2023-08-12 |
Not clear |
| Paolo Calabresi, Massimiliano Di Filippo, Veronica Ghiglieri, Nicola Tambasco, Barbara Piccon. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. The Lancet. Neurology. vol 9. issue 11. 2010-11-16. PMID:20880751. |
however, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias. |
2010-11-16 |
2023-08-12 |
Not clear |
| K Tayarani-Binazir, M J Jackson, S Rose, A C McCreary, P Jenne. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Experimental neurology. vol 226. issue 2. 2010-11-12. PMID:20843474. |
the partial dopamine agonist pardoprunox (slv308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in mptp treated common marmosets. |
2010-11-12 |
2023-08-12 |
Not clear |
| K Tayarani-Binazir, M J Jackson, S Rose, A C McCreary, P Jenne. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Experimental neurology. vol 226. issue 2. 2010-11-12. PMID:20843474. |
dopamine agonist treatment in early parkinson's disease (pd) induces less dyskinesia than l-dopa. |
2010-11-12 |
2023-08-12 |
Not clear |
| K Tayarani-Binazir, M J Jackson, S Rose, A C McCreary, P Jenne. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Experimental neurology. vol 226. issue 2. 2010-11-12. PMID:20843474. |
however, once dyskinesia has developed, dopamine agonists administered with l-dopa exacerbate involuntary movements. |
2010-11-12 |
2023-08-12 |
Not clear |